Rephonic
Artwork for IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Pharma, SAI MedPartners
Oncology
Kyverna
Vir Biotechnology
Rare Diseases
Decision Intelligence
Candel Therapeutics
Bayer
Acceleron
Celgene
Lispatercept
Alltrna
Car-T
T Cell Engagers
Keytruda
Eli Lilly
Astrazeneca
Pharma Portfolio
GSK
Trna
Hepatitis Delta

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and u... more

PublishesTwice monthlyEpisodes69Founded7 years ago
Number of ListenersCategories
ScienceMarketingLife SciencesBusiness

Listen to this Podcast

Artwork for IDEA Collider: Innovation & Asymmetric Learning in Pharma

Latest Episodes

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical ... more

YouTube

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolu... more

YouTube

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.

While CAR-T t... more

YouTube

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations.

After the rapid rise and decline of COVID-19 revenues tied ... more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

David Radwaner
Vice President of Strategic Consulting
IDEA Pharma
Episode: The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution
Tom Brockbank
Senior Consultant
IDEA Pharma
Episode: The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution
Reagan Jarvis
Science Founder, CEO of Anocca
Anocca
Episode: Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping
Marianne De Backer
CEO of Vir Biotechnology
Vir Biotechnology
Episode: Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
Warner Biddle
CEO of Kyverna
Kyverna
Episode: Scaling CAR-T for Autoimmune Disease: Warner Biddle on Kyverna’s Breakthrough Strategy
Jennifer Preston
VP of AI Strategy at SAI MedPartners
SAI MedPartners
Episode: AI & Competitive Intelligence in Pharma: Smarter Decision-Making with SAI MedPartners
Michelle Werner
CEO of Alltrna
Alltrna, Flagship Pioneering
Episode: Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner
Jane Butler
Former Celgene marketing leader, later Director of Strategic Initiatives at FingerPaint Branding
Celgene
Episode: Revitalizing Pharma Collaborations: The Reblozyl Case Study
Sekar Kathiresan
Cardiovascular disease pioneer, founder of Verve Therapeutics, now with Lilly
Verve Therapeutics / Lilly
Episode: Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan

Host

Mike Rea
Host of IDEA Collider

Reviews

5.0 out of 5 stars from 8 ratings
  • Best pharma podcast

    Just that really - insightful, great guests who get to talk

    Apple Podcasts
    5
    Mike Rea
    United Kingdom6 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Dense but valuable; best for decision-makers evaluating new platforms and partnerships.
Great guests and practical pharma strategy insights for sponsors and guests alike.
High-quality conversations with leaders shaping biotech and pharma.
Consistently strong on collaboration dynamics and market-shaping lessons for biotech.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Dr. Christian Rommel on Oncology Innovations and Modern Drug Development at Bayer
Q: For anyone who's new to your story, walk us through your journey from your PhD to Bayer, including the roles at Max Planck, Roche, and beyond.
Dr. Rommel describes an academic-to-industry trajectory, emphasizing curiosity, collaboration across discovery and development, and a persistent focus on delivering patient impact. He notes early exposure to the frontier of human disease biology, the importance of integrating data, AI, and diverse teams, and the ongoing shift toward platforms and external partnerships that preserve scientific rigor while accelerating execution.
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
Q: How does the acquisition by Lilly align with Verve's mission to disrupt chronic care and deliver accessible one-time therapies at scale?
Lilly's involvement enables broader reach and scale, supportive pricing and delivery innovations, and integration into a larger portfolio targeting cardiometabolic disease, while preserving the core mission to deliver durable, transformative therapies that could affect hundreds of millions of patients.
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
Q: What was the turning point that convinced GV and later Lilly to back the program?
The turning point was the deep scientific conviction that lifelong, low cholesterol mediated by editing a liver gene could dramatically reduce heart attack risk, demonstrated via early preclinical data and a clear plan to translate that into humans, plus alignment with investors who wanted to back a world-changing approach.
Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
Q: How does Vir plan to commercialize its oncology and hepatitis Delta assets?
The plan includes co-promotional options in the US with partners, advance Hepatitis Delta data through Eclipse as a pathway to US commercialization, and European partnering with Norgene, signaling a balanced, multi-market commercialization strategy.
Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
Q: What was the biggest takeaway from taking on the CEO role during a challenging period?
She describes navigating a biotech winter, downsizing, preserving core capabilities, and emphasizing cash management, patient impact, and a clear set of cultural values to drive resilience and strategic focus.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

A sharp focus on how bold, data-driven thinking accelerates pharma and biotech innovation. Episodes center on strategic decision-making, reverse-engineering successful trial designs, and leveraging AI, partnerships, and novel modalities to outpace competitors. Notable is the emphasis on practical, market-shaping lessons—ranging from PD-1 biology and IO strategies to non-viral gene editing platforms and collaboration dynamics—delivered by senior leaders and researchers who translate complex science into actionable business decisions.

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. BioCentury This Week
2. The Long Run with Luke Timmerman
3. Biotech Hangout
4. The Readout Loud
5. All-In with Chamath, Jason, Sacks & Friedberg

How many episodes of this podcast are there?

this podcast launched 7 years ago and published 69 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. David Radwaner
2. Tom Brockbank
3. Reagan Jarvis
4. Marianne De Backer
5. Warner Biddle
6. Jennifer Preston
7. Michelle Werner
8. Jane Butler

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days